Datamonitor's Global Paints & Coatings industry profile is an essential resource for top-level data and analysis covering the Paints & Coatings industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.
Scope
* Contains an executive summary and data on value, volume and/or segmentation
* Provides textual analysis of Global Paints & Coatings’s recent performance and future prospects
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Includes a five-year forecast of Global Paints & Coatings
* The leading companies are profiled with supporting key financial metrics
* Supported by the key macroeconomic and demographic data affecting the market
Highlights
* Detailed information is included on market size, measured by value and/or volume
* Five forces scorecards provide an accessible yet in depth view of the market’s competitive landscape
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The paints & coatings market consists of liquid and powder based paints, varnishes, and related products used for protective and decorative, industrial and automotive, specialty, or other purposes. The market excludes inks, thinners and raw materials such as pigments and solvents. The architectural & decorative segment consists of products used in homes and buildings, such as interior and exterior paints, primers, sealers, and varnishes. The industrial segment comprises products that are factory-applied to manufactured goods as part of the production process. The specialty segment consists of aerosol paints, marine paints, high-performance maintenance coatings, and automotive refinish paints. The market value is calculated according to end-user prices. Any currency conversions used in the creation of this report have been calculated using constant annual average exchange rates. For the purpose of this report the global figure is deemed to comprise of the Americas, Asia-Pacific and Europe. The Americas comprises Argentina, Brazil, Canada, Chile, Colombia, Mexico, Venezuela, and the US. Europe comprises Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, the Ukraine and the United Kingdom. Asia-Pacific comprises Australia, China, Japan, India, Singapore, South Korea and Taiwan.
Introduction
Chemical Manufacturing in South America industry profile provides top-line qualitative and quantitative summary information including: market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metri ... more
Introduction
Chemical Manufacturing in Eastern Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metr ... more
Introduction
Chemical Manufacturing in North America industry profile provides top-line qualitative and quantitative summary information including: market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metri ... more
As pay-for-delay agreements look to be on the way out of the pharmaceutical industry in Europe and the US, a new report by independent market analyst Datamonitor forecasts that the number of authorized generics (AG) agreements will grow, in tandem with the increasing convergence between bra ... more
As part of the UK government’s drive to save £2.3 billion ($3.4 billion) in the National Health Service (NHS) during 2010–11, £550m ($800m) will be cut from the prices of branded drugs as a result of the revised Pharmaceutical Price Regulation Scheme (PPRS) included in Alistair Darling’s 20 ... more
In recent years, Pharma has begun to adapt its business model in response to growing industry constraints and the decline of primary-care focused blockbuster therapy. This process of change has recently been disrupted by unprecedented challenges caused by the global economic downturn and Pr ... more